Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in adults with non-obstructive hypertrophic cardiomyopathy
NL-OMON58864Phase 3Completed
- Sponsor
- MyoKardia
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by MyoKardia. Primary endpoints: Change from baseline in KCCQ CSS at Week 48 and Change from baseline in pVO2 at Week 48. Started Aug 2023; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON58864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58864.